Floatz logo

Capecitabine

Cognitive Decline

Pusan National University Yangsan HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Cognitive Decline cohort.

Asset / SponsorPhaseRating
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB
Lipitor
Monash University
Phase 4BB
Arestin
University of Cincinnati
Phase 2BB
FLORTAUCIPIR
University of Pennsylvania
Phase 2BB
Rosuvastatin
Hospital Moinhos de Vento
Phase 3B

View all 19 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →